Bioverativ (BIVV) Posts Quarterly Earnings Results, Beats Expectations By $0.73 EPS
Bioverativ (NASDAQ:BIVV) posted its quarterly earnings results on Tuesday. The biotechnology company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.73, Bloomberg Earnings reports. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%.
Shares of Bioverativ (NASDAQ:BIVV) opened at $103.70 on Wednesday. Bioverativ has a 52-week low of $43.52 and a 52-week high of $104.30.
BIVV has been the topic of several analyst reports. Royal Bank of Canada increased their price target on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, January 18th. Zacks Investment Research lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Jefferies Group increased their price target on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a research report on Thursday, January 18th. Raymond James Financial lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $65.00 price target on shares of Bioverativ in a research report on Thursday, January 18th. Thirteen equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $63.15.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.